scholarly article | Q13442814 |
P50 | author | Catherine Creuzot-Garcher | Q64866954 |
P2093 | author name string | Marc Labetoulle | |
Christophe Baudouin | |||
Pierre-Jean Pisella | |||
Dahlia Ismail | |||
Mourad Amrane | |||
Serge Doan | |||
Beatrice Cochener-Lamard | |||
P2860 | cites work | Topical cyclosporine: are all indications justified? | Q87154377 |
TFOS DEWS II Diagnostic Methodology report | Q38652978 | ||
TFOS DEWS II Epidemiology Report | Q38652994 | ||
TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease | Q38816983 | ||
TFOS DEWS II Management and Therapy Report | Q39453364 | ||
Evaluation of topical cyclosporine for the treatment of dry eye disease | Q44443222 | ||
Antiinflammatory therapy for dry eye. | Q44763839 | ||
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. | Q54222666 | ||
Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review | Q26770830 | ||
Associations between signs and symptoms of dry eye disease: a systematic review | Q26781979 | ||
The pathophysiology, diagnosis, and treatment of dry eye disease | Q28083825 | ||
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome | Q33592784 | ||
Safety and efficacy of cyclosporine in the treatment of chronic dry eye. | Q33825538 | ||
Diagnosing the severity of dry eye: a clear and practical algorithm | Q34092386 | ||
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | Q34443357 | ||
Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests | Q35542950 | ||
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb | Q35854966 | ||
Etiology, prevalence, and treatment of dry eye disease | Q37288773 | ||
Treatment of dry eye disease by the non-ophthalmologist | Q37317581 | ||
Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up | Q37471561 | ||
Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | Q38151227 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cyclosporine | Q367700 |
eye disease | Q3041498 | ||
P304 | page(s) | 289-299 | |
P577 | publication date | 2018-02-05 | |
P1433 | published in | Clinical Ophthalmology | Q5133782 |
P1476 | title | Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. | |
P478 | volume | 12 |
Search more.